Asset Details
Do you wish to reserve the book?
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled Study
Do you wish to request the book?
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled Study
2010
Overview
Abstract
Rationale
Gastroesophageal reflux disease (GERD) is common among patients with asthma; however, studies investigating the effect of proton pump inhibitors on asthma outcomes report conflicting results.
Objectives
To investigate the effect of esomeprazole 40 mg once or twice daily on asthma outcomes in patients with concomitant symptoms of GERD.
Methods
This 26-week, randomized, double-blind, placebo-controlled study (NCT00317044) included adult patients (18–70 yr) with moderate-to-severe asthma and symptomatic GERD. The change in morning peak expiratory flow (primary variable), evening peak expiratory flow, FEV1, asthma symptoms, Asthma Quality of Life Questionnaire, Reflux Disease Questionnaire, and tolerability were assessed.
Measurements and Main Results
A total of 961 patients were randomized and 828 completed the study. Relative to baseline, improvement in morning peak expiratory flow was observed for both esomeprazole 40 mg once daily (+3.5 L/min; 95% CI, −3.2 to 10.2) and 40 mg twice daily (+5.5 L/min; 95% CI, −1.2 to 12.2), although no statistically significant between-treatment differences were apparent. At treatment end, both doses of esomeprazole significantly improved FEV1 versus placebo (+0.09 L and +0.12 L; P = 0.0039 and P < 0.0001, respectively). However, only esomeprazole 40 mg twice daily demonstrated a significant improvement when FEV1 was calculated over the entire 26-week period (+0.07 L; P = 0.0042). Significant improvements in Asthma Quality of Life Questionnaire total score were demonstrated for both esomeprazole doses compared with placebo (+0.28 and +0.41; P = 0.0006 and P < 0.0001, respectively).
Conclusions
Esomeprazole may improve pulmonary function and asthma-related quality of life. However, the improvements were minor and of small clinical significance.
Clinical trial registered with www.clinicaltrials.gov (NCT00317044).
Publisher
Oxford University Press,American Thoracic Society
Subject
/ Adult
/ Aged
/ Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Antacids
/ Anti-Ulcer Agents - administration & dosage
/ Asthma
/ Biological and medical sciences
/ Blood. Blood coagulation. Reticuloendothelial system
/ Esomeprazole - administration & dosage
/ Female
/ Forced Expiratory Volume - drug effects
/ Gastroesophageal Reflux - complications
/ Gastroesophageal Reflux - drug therapy
/ Gastroesophageal Reflux - physiopathology
/ Humans
/ Male
/ Patients
/ Pharmacology. Drug treatments
/ Placebos
/ Proton Pump Inhibitors - administration & dosage
/ Protons
/ Steroids
